- Home
- FBGL vs NXTC Comparison
FBGL vs NXTC Comparison
Compare FBGL & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBGL
- NXTC
- Stock Information
- Founded
- FBGL 1996
- NXTC 2015
- Country
- FBGL Singapore
- NXTC United States
- Employees
- FBGL N/A
- NXTC N/A
- Industry
- FBGL Miscellaneous manufacturing industries
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- FBGL Consumer Discretionary
- NXTC Health Care
- Exchange
- FBGL Nasdaq
- NXTC Nasdaq
- Market Cap
- FBGL 23.6M
- NXTC 21.6M
- IPO Year
- FBGL 2025
- NXTC 2019
- Fundamental
- Price
- FBGL $1.02
- NXTC $0.72
- Analyst Decision
- FBGL
- NXTC Strong Buy
- Analyst Count
- FBGL 0
- NXTC 2
- Target Price
- FBGL N/A
- NXTC $4.00
- AVG Volume (30 Days)
- FBGL 1.9M
- NXTC 61.8K
- Earning Date
- FBGL 01-01-0001
- NXTC 03-20-2025
- Dividend Yield
- FBGL N/A
- NXTC N/A
- EPS Growth
- FBGL N/A
- NXTC N/A
- EPS
- FBGL 0.04
- NXTC N/A
- Revenue
- FBGL $15,607,369.00
- NXTC N/A
- Revenue This Year
- FBGL N/A
- NXTC N/A
- Revenue Next Year
- FBGL N/A
- NXTC N/A
- P/E Ratio
- FBGL $31.33
- NXTC N/A
- Revenue Growth
- FBGL 25.78
- NXTC N/A
- 52 Week Low
- FBGL $0.87
- NXTC $0.66
- 52 Week High
- FBGL $5.45
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- FBGL N/A
- NXTC 40.34
- Support Level
- FBGL N/A
- NXTC $0.66
- Resistance Level
- FBGL N/A
- NXTC $0.79
- Average True Range (ATR)
- FBGL 0.00
- NXTC 0.06
- MACD
- FBGL 0.00
- NXTC 0.00
- Stochastic Oscillator
- FBGL 0.00
- NXTC 42.21
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.